General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible.
Last updated October 13, 2021
Zolgensma (onasemnogene abeparvovec)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Spinal Muscular Atrophy
Last updated October 8, 2021
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate
Last updated October 5, 2021
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Last updated October 5, 2021
Atectura Breezhaler (indacaterol /mometasone furoate)
Status:
Concluded with an LOI
Manufacturer:
Valeo Pharma Inc.
Indication:
Asthma
Last updated September 30, 2021
Enerzair Breezhaler (indacaterol/glycopyrronium/mometasone furoate)
Status:
Concluded with an LOI
Manufacturer:
Valeo Pharma Inc.
Indication:
Asthma
Last updated September 30, 2021
Status:
Negotiations were not pursued
Manufacturer:
AbbVie Corporation
Indication:
Acute myeloid leukemia (AML) Newly diagnosed in patients who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy (In combination with low-dose cytarabine)
Last updated September 28, 2021
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Conception Control
Last updated September 20, 2021
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis, F508del CFTR mutation
Last updated September 17, 2021
Status:
Concluded without agreement
Manufacturer:
Allergan Inc.
Indication:
Migraine, Chronic
Last updated September 17, 2021